At Tango, we are committed to patient health, safety and well-being. The patient is part of our process from discovery through to development, and we focus our research and development on areas where we can make a difference in the lives of patients with few or no effective therapeutic options.
We are developing and testing oncology medicines to expand the treatment options for those living with cancer.
BRCA 1/2-mutant and other HRD+ cancers
Evaluating safety, pharmacokinetics, pharmacodynamics and efficacy of TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant and other HRD+ (homologous recombination deficient) cancers.
STK-11 mutant cancers
Evaluating safety, pharmacokinetics, pharmacodynamics and efficacy of TNG260, with a one cycle single agent run-in phase to evaluate the safety and PK of TNG260, in combination with pembrolizumab, in patients with locally advanced or metastatic solid tumors with an STK11 loss-of-function mutation.
MTAP-deleted cancers
Evaluating safety, pharmacokinetics, pharmacodynamics and efficacy of TNG462 in patients with solid tumors with MTAP deletions.
MTAP-deleted cancers
Evaluating safety, pharmacokinetics, pharmocodynamics, and preliminary clinical activity of TNG908 in patients with MTAP-deleted cancers.
Currently, participation in a clinical trial is the only way to receive Tango investigational therapies and until safety and efficacy data become available, we will not be making our investigational therapies available in other ways. If you have questions about participating in a clinical trial, please speak to your treating physician or contact clinicaltrials@tangotx.com.
